ADC Therapeutics (ADCT) Current Leases (2022 - 2023)
ADC Therapeutics' (ADCT) quarterly Current Leases came in at $1.5 million in Q4 2023, up 33.73% year-over-year from $1.1 million in Q4 2022, and up 33.73% quarter-over-quarter from $1.1 million in Q4 2022.
Powered by 
Analysis
ADC Therapeutics (ADCT) Current Leases (2022 - 2023) Analysis & Trends
ADC Therapeutics has disclosed Current Leases across 2 years of filings, most recently posting $1.5 million for Q4 2023.
- In Q4 2023, Current Leases rose 33.73% year-over-year to $1.5 million; the TTM figure through Dec 2023 stood at $1.5 million (up 33.73% YoY), while the FY2023 annual figure was $1.5 million, up 33.73% from the prior year.
- Current Leases came in at $1.5 million for Q4 2023 at ADC Therapeutics, up from $1.1 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $1.5 million in Q4 2023 to a low of $1.1 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.27 Mn |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | - |